- patients who weighed between 132 and 220 lb (60 and 100 kg) with benign prostatic
hyperplasia (BPH)
- a total PSA (prostate specific antigen) measurement of less than or equal to 10 µg/L
within the 12 months prior to screening, were currently on doxazosin treatment for
BPH, had been treated with doxazosin for a minimum of 2 months prior to first dose of
study medication, and had received a minimum of 4 mg doxazosin once daily (from
doxazosin supplied for this study) for 2 weeks prior to the first dose of study
medication.
- subjects with a recent history (i.e. within 6 months prior to screening) of stroke or
myocardial infarction
- subjects with severe cardiovascular disorders such as unstable angina or severe
congestive heart failure
- subjects with known hereditary degenerative retinal disorders, such as retinitis
pigmentosa
- subjects with a supine systolic/diastolic blood pressure of >170/100 mmHg or mmHg either at screening or at the pre-dose measurements
- subjects receiving any other antihypertensive therapy other than doxazosin in the 3
weeks prior to the first dose of study medication.